{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T18:11:03Z","timestamp":1792001463926,"version":"4.4.0"},"reference-count":24,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T00:00:00Z","timestamp":1752624000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004948","name":"Astellas Pharma","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004948","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100022789","name":"Pfizer Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100022789","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004324","name":"Astellas Pharma US Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004324","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ejca.2025.115603","type":"journal-article","created":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T17:07:11Z","timestamp":1752599231000},"page":"115603","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["Enfortumab vedotin in patients with advanced non-small cell lung cancer after disease progression on platinum- and PD-1\/PD-L1 inhibitor-containing regimens: Phase 2 international multicenter EV-202 study"],"prefix":"10.1016","volume":"227","author":[{"given":"Kei","family":"Muro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trevor","family":"Feinstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0917-6307","authenticated-orcid":false,"given":"Joaquina","family":"Baranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1215-9495","authenticated-orcid":false,"given":"Ioana","family":"Bonta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Noriko","family":"Yanagitani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd","family":"Gersten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leena","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Kudo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3277-6754","authenticated-orcid":false,"given":"Naomi","family":"Fujioka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3085-7147","authenticated-orcid":false,"given":"Jason","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5256-2189","authenticated-orcid":false,"given":"Seema","family":"Gorla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shubin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Wozniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srinivasu","family":"Poondru","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Dillon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9438-5719","authenticated-orcid":false,"given":"Changting","family":"Meng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4389-1010","authenticated-orcid":false,"given":"Tejas","family":"Patil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2025.115603_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.ejca.2025.115603_bib2","unstructured":"Global Cancer Observatory: Global Cancer Observatory website. In. 2025."},{"key":"10.1016\/j.ejca.2025.115603_bib3","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.ccell.2022.09.018","article-title":"Squamous cell lung cancer: current landscape and future therapeutic options","volume":"40","author":"Lau","year":"2022","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2025.115603_bib4","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/j.mayocp.2019.01.013","article-title":"Non-small cell lung cancer: epidemiology, screening, diagnosis, and treatment","volume":"94","author":"Duma","year":"2019","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ejca.2025.115603_bib5","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1056\/NEJMoa1801005","article-title":"Pembrolizumab plus chemotherapy in metastatic non-small-cell lung cancer","volume":"378","author":"Gandhi","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115603_bib6","doi-asserted-by":"crossref","first-page":"249","DOI":"10.6004\/jnccn.2204.0023","article-title":"Non-small cell lung cancer, version 4.2024, NCCN clinical practice guidelines in oncology","volume":"22","author":"Riely","year":"2024","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ejca.2025.115603_bib7","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab vedotin antibody-drug conjugate targeting nectin-4 is a highly potent therapeutic agent in multiple preclinical cancer models","volume":"76","author":"Challita-Eid","year":"2016","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2025.115603_bib8","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab vedotin in previously treated advanced urothelial carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115603_bib9","series-title":"In Society for Immunotherapy of Cancer (SITC)","article-title":"Enfortumab vedotin induces immunogenic cell death, elicits antitumor immune memory, and shows enhanced preclinical activity in combination with immune checkpoint inhibitors","author":"Olson","year":"2022"},{"key":"10.1016\/j.ejca.2025.115603_bib10","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2025.115603_bib11","unstructured":"Padcev\u00ae (enfortumab vedotin) [package insert]. Astellas Pharma US, Inc., Northbrook, IL, USA; 2023 In."},{"key":"10.1016\/j.ejca.2025.115603_bib12","unstructured":"PADCEV [Enfortumab vedotin]. Summary of product characteristics; European Medicines Agency, 2024. Astellas Pharma Europe B.V; Leiden, The Netherlands. In."},{"key":"10.1016\/j.ejca.2025.115603_bib13","unstructured":"Swiecicki P.L., Yilmaz E., Rosenberg A.J. et al. Phase II Trial of Enfortumab Vedotin in Patients With Previously Treated Advanced Head and Neck Cancer. J Clin Oncol 2024; JCO2400646."},{"key":"10.1016\/j.ejca.2025.115603_bib14","doi-asserted-by":"crossref","first-page":"3302","DOI":"10.1002\/sim.7338","article-title":"BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints","volume":"36","author":"Zhou","year":"2017","journal-title":"Stat Med"},{"key":"10.1016\/j.ejca.2025.115603_bib15","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1016\/j.jtho.2016.05.024","article-title":"Clinicopathologic features of advanced squamous NSCLC","volume":"11","author":"Socinski","year":"2016","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2025.115603_bib16","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.jtho.2017.11.111","article-title":"Current and emergent therapy options for advanced squamous cell lung cancer","volume":"13","author":"Socinski","year":"2018","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.ejca.2025.115603_bib17","doi-asserted-by":"crossref","first-page":"e198","DOI":"10.1200\/EDBK_237829","article-title":"New treatment options in advanced squamous cell lung cancer","volume":"39","author":"Paik","year":"2019","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.ejca.2025.115603_bib18","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1200\/JCO-24-01544","article-title":"Datopotamab deruxtecan versus docetaxel for previously treated advanced or metastatic non-small cell lung cancer: the randomized, open-label phase III TROPION-Lung01 study","volume":"43","author":"Ahn","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115603_bib19","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.annonc.2023.10.004","article-title":"SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer","volume":"35","author":"Borghaei","year":"2024","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2025.115603_bib20","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.lungcan.2017.05.021","article-title":"Treatment outcomes by histology in REVEL: a randomized phase III trial of Ramucirumab plus docetaxel for advanced non-small cell lung cancer","volume":"112","author":"Paz-Ares","year":"2017","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ejca.2025.115603_bib21","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.1200\/JCO.23.02166","article-title":"CONTACT-01: a randomized phase III trial of atezolizumab + cabozantinib versus docetaxel for metastatic non-small cell lung cancer after a checkpoint inhibitor and chemotherapy","volume":"42","author":"Neal","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115603_bib22","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal trial of enfortumab vedotin in urothelial carcinoma after platinum and anti-programmed death 1\/programmed death ligand 1 therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115603_bib23","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1200\/JCO.19.02044","article-title":"EV-101: a phase I study of single-agent enfortumab vedotin in patients with nectin-4-positive solid tumors, including metastatic urothelial carcinoma","volume":"38","author":"Rosenberg","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2025.115603_bib24","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s40262-024-01369-0","article-title":"Clinical pharmacology of the antibody-drug conjugate enfortumab vedotin in advanced urothelial carcinoma and other malignant solid tumors","volume":"63","author":"Tang","year":"2024","journal-title":"Clin Pharm"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925003855?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804925003855?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T01:32:26Z","timestamp":1777599146000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804925003855"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":24,"alternative-id":["S0959804925003855"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115603","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enfortumab vedotin in patients with advanced non-small cell lung cancer after disease progression on platinum- and PD-1\/PD-L1 inhibitor-containing regimens: Phase 2 international multicenter EV-202 study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2025.115603","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"115603"}}